Search the Newsreel

Insider plans 58,258-share stock sale (NASDAQ: CUE) under Rule 144

An insider of Cue Biopharma (NASDAQ: CUE) has filed a Rule 144 notice to sell up to 58,258 shares of common stock. These shares originated from restricted stock units that vested on August 1, 2026. The sale is planned to occur in two tranches …

Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Cue Biopharma reported its second-quarter 2026 financial results, highlighting a significant increase in revenue due to a collaboration milestone and higher expenses related to the CUE-221 development program. The company also announced the submission of an IND for CUE-221 in food allergy applications, a …

Driehaus Capital discloses 6.96% Cue Biopharma (CUE) holding in Schedule 13G

Driehaus Capital Management LLC has disclosed a 6.96% beneficial ownership stake in Cue Biopharma, Inc. (CUE), amounting to 292,144 shares. This holding is reported on a Schedule 13G filing, indicating a passive investment. The shares are held in fully discretionary accounts for investment advisory …

Cue Biopharma, Inc. SEC Filing (Aug 14, 2026)

This article reports on a Form 144 SEC filing by Cue Biopharma, Inc. (CUE) on August 14, 2026. The filing indicates a proposed sale of 8,829 shares of common stock with an aggregate market value of $266,106.06, acquired through Restricted Stock Units vesting under …

Cue Biopharma (CUE) registers 1.51M shares for stockholder resale after $50M raise

Cue Biopharma (CUE) has filed a shelf registration to allow existing investors to resell up to 1.51 million shares of common stock, stemming from a $50 million private placement in July 2026. The company will not receive proceeds from these resales, except for nominal …

Cue Biopharma (CUE) Expected to Announce Earnings on Tuesday

Cue Biopharma (NASDAQ:CUE) is set to release its Q2 2026 earnings before market open on Tuesday, August 18th. Analysts anticipate a loss of $1.69 per share and $3.00 million in revenue. The company previously exceeded expectations in Q1, reporting a smaller loss and higher …

Cue Biopharma (NASDAQ:CUE) Trading Down 3.8% - Should You Sell?

Cue Biopharma (NASDAQ:CUE) shares dropped 3.8% to $26.10 in midday trading on Monday, with trading volume significantly higher than average. The company's stock is trading well below its 50-day and 200-day moving averages, and analyst sentiment is predominantly "Sell" despite a recent beat on …

Cue Biopharma Inc (CUE) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cue Biopharma Inc (CUE), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights an expected revenue of $3.00M for the next quarter, an average price target of $5.00, and a "Buy" trend …

Cue Biopharma Inc (CUE) Stock News Today

This article provides current stock news for Cue Biopharma Inc (CUE), including its stock price, market cap, and recent performance. It also lists "Amgen Inc Stock (AMGN) Opened Down by 4.69% on May 1: A Full Analysis" as a relevant news item. The piece …

Fortescue (ASX:FMG) Dividend Watch: What Does a Fully Franked Yield Mean for ASX Income Seekers?

Cue Biopharma Appoints Veteran James Ahlers as CFO

Cue Biopharma has appointed James Ahlers as its new Chief Financial Officer, effective July 30, 2026. Ahlers brings extensive experience in life sciences finance, including IPO preparation and SEC compliance, and will receive a base salary of $450,000 along with equity incentives. This appointment …

Cue Biopharma CFO James M. Ahlers files initial beneficial ownership statement

Cue Biopharma's CFO, James M. Ahlers, filed an initial Form 3 statement of beneficial ownership dated July 30, 2026. This news brief was generated by Public Technologies (PUBT) using AI and is for informational purposes only. The original content was published by Cue Biopharma …

Cue Biopharma (CUE) hires James Ahlers as CFO with equity and severance package

Cue Biopharma, Inc. has appointed James Ahlers as its new Chief Financial Officer, effective July 30, 2026. Ahlers brings extensive experience in biotech finance and will receive an annual base salary of $450,000, along with equity grants including nonstatutory stock options for 51,000 shares …

Cue Biopharma names James Ahlers as chief financial officer By Investing.com

Cue Biopharma has appointed James M. Ahlers as its new Chief Financial Officer. Ahlers brings over 25 years of financial leadership experience in the biotechnology sector. His appointment coincides with the company's submission of an Investigational New Drug application for CUE-221 and anticipated Phase …

Cue Biopharma Appoints James M. Ahlers as Chief Financial Officer

Cue Biopharma, Inc. has announced the appointment of James M. Ahlers as its new Chief Financial Officer, effective immediately. Ahlers brings over 25 years of financial leadership experience in the biotechnology sector and will support the company's strategic growth, including its recent IND submission …

Cue Biopharma Inc (CUE) Financial Health: Profitability & Balance Sheet Analysis

Cue Biopharma Inc (CUE) has a robust financial status with a current financial score of 9.20, ranking 12th in the Biotechnology & Medical Research industry. Its latest quarterly revenue saw a significant year-over-year increase of 1250.59% to 5.69M, and its net profit increased by …

CUE|Cue Biopharma Inc|Price:28.600|Chg%:+0.590

Cue Biopharma Inc. (CUE) shows healthy fundamentals and high growth potential, despite a recent stock price decline. The company's valuation is considered fairly valued within the Biotechnology & Medical Research industry, with high institutional ownership and a "Buy" rating from analysts. Its Immuno-STAT platform …

Cue Biopharma Inc (CUE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cue Biopharma Inc (CUE), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. According to the analysis, CUE's stock is currently trading between a resistance level of 41.93 and a …

CUE|Cue Biopharma Inc|Price:30.340|Chg%:-2.230

This article provides a market overview of Cue Biopharma Inc (CUE), detailing its real-time stock quotes, trading strategies, and related analysis. It highlights the company's strong fundamentals, high growth potential, and a 'Buy' rating from analysts with a target price of $115.00. The company, …

Cue Biopharma Inc (CUE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Cue Biopharma Inc (CUE), listing its major shareholders and institutional holdings. It provides a breakdown of shareholder types by proportion and tracks institutional shareholding changes over several quarters. The report also highlights recent shareholder activity and related …

Cue Biopharma Inc (CUE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey reports on Cue Biopharma Inc (CUE) and its revenue breakdown. However, it explicitly states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The article provides current stock performance and …

Cue Biopharma Market Sentiment

This article provides an overview of market sentiment for Cue Biopharma (CUE), including analyst consensus, short interest, options flow, and insider activity. Analysts show a "Buy" consensus with an average price target of $4, while short interest is rising at 7.7%. Recent analyst actions …

Cue Biopharma Inc (CUE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Cue Biopharma Inc's (CUE) dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years and notes a significant merger-related stock split event scheduled for April 22, 2026, …

CUE|Cue Biopharma Inc|Price:32.350|Chg%:-0.740

This article provides a detailed financial overview of Cue Biopharma Inc (CUE), including its stock price, market capitalization, and key financial summaries. It presents quarterly and annual data for income statements, balance sheets, and cash flow statements, along with analyst ratings and upcoming earnings …

Cue Biopharma Inc (CUE) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Cue Biopharma Inc (CUE), indicating a current valuation score of 9.96, ranking it 3rd within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -0.90, noting its fluctuation relative to recent highs …

Fortescue Ltd Revenue Breakdown – ASX:FMG

Enterprise value to EBITDA forward of Cue Biopharma, Inc. – DUS:1UC0

This article provides access to the "Enterprise value to EBITDA forward" financial metric for Cue Biopharma, Inc. (DUS:1UC0) on the TradingView platform. It highlights that the market was closed with no trades at the time of viewing. The content primarily focuses on navigation to …

Cue Biopharma (CUE) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for Cue Biopharma (CUE). It includes detailed financial analysis, price targets, performance breakdown, and a consensus from various analysts. The report also touches upon insider transactions and dividend information related to CUE.

Fortescue (ASX:FMG) Shares Rally With Iron Ore — Can the Momentum Continue?

Cue Biopharma, Inc. announced that it has received $49.999926 million in funding from Cormorant Asset Management, LP, Threadneedle Asset Management Limited

Cue Biopharma, Inc. has successfully secured $49.999926 million in funding from Cormorant Asset Management, LP, and Threadneedle Asset Management Limited. The transaction, involving four investors, closed on July 22, 2026. This funding will support the clinical-stage biopharmaceutical company's ongoing development of novel injectable biologics …

Cue Biopharma (CUE) completes $49,999,927 Reg D Rule 506(b) raise

Cue Biopharma, a biotechnology company, has successfully completed a private securities offering, raising $49,999,927. The offering was conducted under Regulation D, Rule 506(b), indicating it involved equity, warrants, or other rights to acquire securities, and was fully subscribed with $0 remaining to be sold. …

ETFs Investing in Cue Biopharma, Inc. Stocks

This article lists Exchange Traded Funds (ETFs) that hold Cue Biopharma, Inc. (CUE) stock, providing an overview of funds, their market value, weight, issuer, and expense ratio. It highlights how ETFs offer accessible and diversified investment opportunities with lower risk. The iShares Microcap ETF …